Combined liver transplantation and sleeve gastrectomy for end-stage liver disease in a bariatric patient: First European case-report  by Tariciotti, Laura et al.
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INTRODUCTION:  Obesity  is a contributor  to the  global  burden  of chronic  diseases,  including  non-alcoholic
fatty  liver  disease  and  non-alcoholic  steatohepatitis  (NASH).  NASH  cirrhosis  is  becoming  a  leading  indica-
tion  for  liver  transplant  (LT).  Obese  transplanted  patients  have  higher  morbidity  and  mortality  rates.  One
strategy,  to improve  the outcomes  in these  patients,  includes  bariatric  surgery  at the  time  of LT. Herein
we  report  the  ﬁrst  European  combined  LT  and sleeve  gastrectomy  (SG).
CASE PRESENTATION:  A 53  years  old  woman  with  Hepatocellular  carcinoma  and  Hepatitis  C  virus  related
cirrhosis,  was  referred  to  our  unit.  She  also  presented  with  severe  morbid  obesity  (BMI  40  kg/m2) and
insulin-dependent  diabetes.  Once  listed  for LT,  she  was  assessed  by the bariatric  surgery  team  to  undergo
a combined  LT/SG.  At  the  time  of  transplantation  the  patient  had  a model  for  end-stage  liver disease
calculated  score  of  14 and  a BMI  of  38 kg/m2.
The LT  was  performed  using  a deceased  donor.  An experienced  bariatric  surgeon,  following  completion
of the  LT,  performed  the  SG.  Operation  time  was  8 h and  50 min.  The  patient  had  an  uneventful  recovery
and  is  currently  alive,  5 months  after  the  combined  procedure,  with  normal  allograft  function,  signiﬁcant
weight  loss  (BMI  = 29  kg/m2),  and  diabetes  resolution.
CONCLUSION:  Despite  the  ideal  approach  to the management  of  the obese  LT  patients  remains  unknown,
we  strongly  support  the  combined  procedure  during  LT in selected  patients,  offering  advantages  in  terms
of allograft  and patient  survival,  maintenance  of weigh  loss  that  will  ultimately  reduce  obese  related
co-morbidities.
© 2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
The current obesity epidemic is one of the greatest public health
oncerns of our century [1]. In Europe, obesity has reached epi-
emic proportions [2]. The prevalence of obesity, deﬁned as body
ass index (BMI) ≥ 30 kg/m2, varies between 6% and 20%, with
igher prevalence in Central and Eastern Europe [3]. If the observed
rends of increasing prevalence of obesity persist, by 2030 the abso-
ute number of obese individuals could rise to a total of 1.12 billion,
ccounting for 20% of the world’s adult population [4].
Obesity is a major contributor to the global burden of chronic
iseases and disabilities, including non-alcoholic fatty liver disease
NAFLD).NAFLD encompasses a spectrum of liver injuries that range from
enign steatosis to non-alcoholic steatohepatitis (NASH). NASH cir-
hosis marks the ﬁnal stage within the spectrum of NAFLD, and
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is becoming a leading indication for liver transplant (LT) in the
United States [5], being currently the third most common indica-
tion for liver transplantation, and it is expected to become the most
common indication for LT within the next 1–2 decades.
A high proportion of obese patients are a priori excluded from
LT because of co-morbidities. Obesity is in fact strongly associ-
ated with diabetes, heart disease and cancer, which are leading
causes of morbidity and mortality post-LT [6]. One strategy, aim-
ing to improve the outcomes in this category of patients, includes
bariatric surgery at the time of LT as described for the ﬁrst time by
Heimbach et al. [7], reporting their experience of combined LT and
gastric sleeve resection (SG) in 7 patients with BMI  greater than
35 kg/m2.
The beneﬁts of combined surgery are that it involves a sin-
gle operation and recovery for the patient, and therefore avoids
a potentially harsher re-operative ﬁeld, as well as avoiding delays
due to complications such as rejection, infection, renal insufﬁciency
or disease recurrence or other barriers to weight loss surgery such
as insurance coverage and patient hesitation to undergo yet another
invasive procedure.
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Gastrograﬁn study following sleeve gastrectomy showing absence of leakage.
Fig. 2. BMI  Trend.
Table 1
Patient and Donor details.
Before LT Day1 Day7 1 Month 3 Months 5 Months
AST U/L 22 4382 102 37 26 18
ALT  U/L 21 2145 106 27 32 23
Bilirubin mg/dl 1,17 2,8 5 0,99 0,87 0,52
GGT  UI/L 35 133 644 190 78 44
ALP  UI/L 159 125 216 116 75 59
Creatinine
mg/dl
0,75  1,3 1,16 0,65 0,39 0,96
INR  1,82 3,9 2,85 2,43 1,61 1,62
HbA1c
mmol/mol
55  – 51 45 37 28
˛fetoproteine
UI/ml
11,5  – – 3,4 2,9 2,2
Donor HLA
typing
Recipient HLA
A2 A23 B44 B57 Cw5 Cw7 DR7 DR13 DQ7  DQ9
A11 A25 B13 B18 Cw7 DR7 DR11 DQ2 DQ7CASE  REPORT
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Herein we report to the best of our knowledge the ﬁrst European
ombined LT and SG.
. Case report
A Caucasian 53 years old woman was referred to our Transplant
nit with Hepatocellular carcinoma (HCC), inside Milan criteria,
hich was assessed with whole body CT scan and bone scintigraphy
xcluding the presence of metastasis. Hepatitis C virus (HCV) geno-
ype 1b infection was diagnosed 6 years earlier; at the time of listing
he patient presented a sustained viral response (SVR12) after 24
eeks combination of sofosbuvir and ledipasvir plus ribavirin.
The patient presented grade 2 oesophageal varices at
ndoscopy. Her medical history also included a long-standing
evere morbid obesity with a BMI  of 40 kg/m2 with type 2 diabetes
insulin-dependent) and no other comorbities.
A multidisciplinary team (including dietician, psychologist and
ariatric surgeon) assessed the patient, who had a dietary pattern of
big eater”, therefore with a great risk of failure to maintain weigh
oss after transplant, thus she was listed for LT with a combined
G. Nevertheless a dietary education was provided by an experi-
nced transplant dietician during the ﬁrst evaluation, requiring the
atient to follow a calorie-restricted diet to reduce the BMI  before
urgery.
A month later she was listed for LT, we proceeded to a combined
T plus SG. At the time of transplantation the patient had a model
or end-stage liver disease (MELD) calculated score of 14 and a BMI
f 38 kg/m2.
The LT/SG was performed using a whole liver (1754 gr) from
 54 years old deceased donor, using a right subcostal incision,
ith a caval sparing hepatectomy (brieﬂy clamping the portal vein
ithout the need for a temporary porto-caval shunt) and a duct to
uct biliary anastomosis. The SG was performed by an experienced
ariatric surgeon following completion of the LT. The greater cur-
ature of the stomach was mobilised up to the left diaphragmatic
rus. Subsequently the resection was done with a combination of
5-mm and 60-mm Endo-GIA staple loads from the antrum up to
he fundus, utilizing a 32 Fr orogastric tube placed along the lesser
urve of the stomach.
A methylene blue test was performed to assess the staple line,
ith no evidence of leakage. Operation time was  8 h and 50 min,
equiring transfusions with 2 units of blood and 10 units of fresh
rozen plasma. The patient received standard immunosuppression
onsisting of tacrolimus once daily and everolimus, with the target
evels of 5–8 ng/mL and 3–8 ng/mL respectively, as per our centre
rotocol. The patient had an uneventful recovery, with no evidence
f leak from the gastric staple line (Fig. 1) and she was discharged
 weeks after the combined procedure. Histological ﬁndings of the
umour were of a moderately differentiated hepatocellularcarci-
oma (Edmonson grade 2), single nodule of 3 × 2.4 × 1.6 cm,  on a
ackground of hepatic cirrhosis.
The patient is currently alive, 5 months after the combined pro-
edure, with normal allograft function, non detectable HCV RNA
evel, showing signiﬁcant weight loss (BMI = 29 kg/m2, BMI  trend is
hown in Fig. 2), no longer requiring insulin or oral hypo-glycemic
reatment; she is actually only on immunosuppression drugs (pre
nd post-LT patient and donor details are showed in Table 1). In
ddition, there is no evidence of steatosis based on protocol ultra-
ound performed during the follow-up.
. DiscussionNAFLD and NASH are increasingly relevant public health issues
wing to their close association with the worldwide epidemic of
besity. As seen in our patient, it is recognized that NAFLD/NASH
typing
AST: aspartate aminotransferase; ALT: alanine transaminase; GGT: gamma-
glutamyl transpeptidase; ALP: alkaline phosphatase; HbA1c: glycated haemoglobin;
HLA: human leukocyte antigens.
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an occur together with other chronic liver diseases, namely HCV
8], and that in some cases, this can exacerbate liver damage [9].
otably, the burden of NAFLD related cirrhosis may  be under-
stimated, as the histological signs of steatohepatitis may no longer
e present at the cirrhotic stage of disease [10], like in this report
ith a patient with long-standing morbid obesity. Moreover, obese
r diabetic patients have an increased risk of HCC [11,12] even in
ssociation with other chronic liver diseases [13]. NAFLD and NASH,
ither de novo or recurrent, are commonly seen also after LT [14,15]
ith BMI  prior and following LT, diabetes mellitus, arterial hyper-
ension and hyperlipidaemia as the major risk factors for post-LT
AFLD/NASH.
Actually there are not speciﬁc recommendation regarding pre-
ention and treatment of NAFLD/NASH in LT recipients, except to
void excessive weight gain.
Moreover, obese transplanted patients have higher morbidity
nd mortality rates compared to those performed in patients with
ormal BMI. This has been described clearly in a recent series of 306
bese liver transplant recipients over 11 years where patient and
raft survival, blood product transfusion, intensive care unit length
f stay, and biliary complications requiring intervention were all
igher in the obese patients [16].
The clinical features of metabolic syndrome, in particular type 2
iabetes, obesity, dyslipidaemia and arterial hypertension, either
lone or in combination contribute to late post-operative mor-
idity and mortality too. The prevalence of metabolic syndrome
ies between 50 and 60% in the LT population [15]. Due to the
igh prevalence of metabolic syndrome and its different clini-
al features, LT recipients have a signiﬁcantly increased risk of
ardiovascular events and mortality compared to an age and
ender-matched general population [17]. Therefore, cardiovascu-
ar disease accounts for almost a quarter of deaths in the long-term
ollow-up after LT [18].
These apprehensions over outcomes in the obese LT recipient
ave led to the advent of weight reduction surgery. Data from
ase series and database reviews have reasonably demonstrated
hat weight reduction surgery in the LT recipient is a feasible
ttempt. However, several questions have been raised regard-
ng the type of weight reduction surgery, timing of surgery in
elation to LT, patient and allograft survival and post-LT main-
enance of weight loss. Early approaches towards combined LT
ith weight reduction surgery have focused on the use of SG as
he weight reduction procedure of choice. Roux-en-Y-bypass and
ilio-pancreatic diversion have largely been eliminated from the
rmamentarium in the LT recipient because of increased complex-
ty with this technique as well as the malabsorption associated
hat may  adversely affect early post-transplant immunosuppres-
ion levels [15,16]; moreover Roux-en-Y gastric bypass has been
escribed to cause hyperammonemia-induced encephalopathy in
ew cases [19], which could be harsher in the transplant setting.
urthermore, a SG is a procedure that does not interfere with future
ccess to the biliary system should post-transplant complications
rise.
In carefully selected patients who have failed a rigorous weight
oss program, or that, despite a possible weight loss prior to LT, have
 greater risk for weight gain following transplant with the asso-
iated metabolic complications, a SG at the time of LT is feasible,
fﬁcient and can be performed with minimal additional operative
ime. Our patient was assessed by a multidisciplinary team and
elieved to be at high risk for weight gain, and the decrease of BMI
n a limited period of time was mainly achieved because she was
ospitalised for the transplant evaluation. Our decision was  also
upported by Heimbach’s series, where, over 3 years of follow-up,
0% of patients who underwent dietary modiﬁcation and LT alone
ere not able to sustain the weight loss after transplant.PEN  ACCESS
urgery Case Reports 28 (2016) 38–41
Weight loss in our patient undergoing combined LT/SG has been
steady and gradual, because SG is only a restrictive procedure.
Whether the weight loss will be maintained will require long-
term follow-up, which is not yet available. We  also managed to
maintain adequate immunosuppression levels, without the difﬁ-
culties encountered in malabsorptive procedures. Moreover, the ab
initio introduction of everolimus, a proliferation–signal inhibitor
with anti-proliferative and immunosuppressive activity [20], has
not determined a leak from the gastric staple line, as we  adopt a
lower dose of mTORi to achieve a trough level of 3–8 ng/mL with-
out an initial loading dose, that can avoid, or at least decrease
well-known mTORi-related adverse events, namely dyslipidaemia,
wound healing complications, incisional hernia and leucopoenia
[21]. The timing of SG in the LT setting, has been also discussed
elsewhere [22]. A greater advantage of weight reduction surgery
can potentially come in the pre-transplant setting. However, at this
stage, there is an increased risk of progressing to decompensated
liver failure, and we  also must take into consideration the effect of
SG on the technical aspects of the future LT. Namely, adhesion for-
mation subsequent to SG can potentially impact the mobilisation
of the left lobe of the liver due to strong adhesions between the
left lobe of the liver and the staple line of the stomach, and may
signiﬁcantly impact porta hepatis dissection. On the other hand, a
SG in the post-transplant scenery, will increase the risk of a more
adverse operative ﬁeld, or could determine delays to weight loss
surgery due to post-LT complications like rejection, infection or
disease recurrence.
In conclusion, despite the ideal approach to the management
of the obese LT patient remains unknown, we  strongly support the
combined procedure during LT in cautiously selected patients, with
beneﬁts that involve a single operation and recovery for the patient,
and may  offer advantages in terms of allograft and patient survival
preventing NASH manifestation, maintenance of weigh loss that
will ultimately reduce obese related co-morbidities.
However, well-designed prospective clinical trials that focus on
the issues highlighted are needed to guide the transplant commu-
nity in the care of these difﬁcult patients who will soon account for
the majority of the patients in our clinics.
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